PNH Patients finally given access to life-saving treatment

The Government announced today that PNH patients eligible to receive Soliris (Eculizumab) treatment will have fully subsidised access from 1 January 2011 through the Life Saving Drugs Program (LSDP).

Eligibility criteria has been developed by the PNH Disease Advisory Committee, chaired by Professor Jeffrey Szer, Director of Clinical Haematology & Bone Marrow Transplants at Royal Melbourne Hospital.  PNH patients should contact their treating specialist to determine their eligibility.

PNH patients have welcomed the news as the best Christmas present ever!  We now have certainty of our future and are able to resume fuller and happier lives.

PLEASE NOTE: The LSDP is a separate program to the Pharmaceutical Benefits Scheme.  Soliris is a hospital-only medication and no co-payment applies.  Patients receive Soliris free of charge in hospital.

The PNHSAA issued a media release today in response to the announcement – read it here

9 December 2010

Back to top ^


Swipe left/right for previous/next post